Cardiovasc Res. 2017 Apr 1;113(5):488-497. doi: 10.1093/cvr/cvw257.
Mechanical factors play significant roles in neointimal hyperplasia after vein grafting, but the mechanisms are not fully understood. Here, we investigated the roles of microRNA-33 (miR-33) in neointimal hyperplasia induced by arterial mechanical stretch after vein grafting.
Grafted veins were generated by the 'cuff' technique. Neointimal hyperplasia and cell proliferation was significantly increased, and miR-33 expression was decreased after 1-, 2-, and 4-week grafts. In contrast, the expression of bone morphogenetic protein 3 (BMP3), which is a putative target of miR-33, and the phosphorylation of smad2 and smad5, which are potential downstream targets of BMP3, were increased in the grafted veins. miR-33 mimics/inhibitor and dual luciferase reporter assay confirmed the interaction of miR-33 and BMP3. miR-33 mimics attenuated, while miR-33 inhibitor accelerated, proliferation of venous smooth muscle cells (SMCs). Moreover, recombinant BMP3 increased SMC proliferation and P-smad2 and P-smad5 levels, whereas BMP3-directed siRNAs had the opposite effect. Then, venous SMCs were exposed to a 10%-1.25 Hz cyclic stretch (arterial stretch) by using the FX4000 cyclic stretch loading system in vitro to mimic arterial mechanical conditions. The arterial stretch increased venous SMC proliferation and repressed miR-33 expression, but enhanced BMP3 expression and smad2 and smad5 phosphorylation. Furthermore, perivascular multi-point injection in vivo demonstrated that agomiR-33 not only attenuates BMP3 expression and smad2 and smad5 phosphorylation, but also slows neointimal formation and cell proliferation in grafted veins. These effects of agomiR-33 on grafted veins could be reversed by local injection of BMP3 lentivirus.
The miR-33-BMP3-smad signalling pathway protects against venous SMC proliferation in response to the arterial stretch. miR-33 is a target that attenuates neointimal hyperplasia in grafted vessels and may have potential clinical applications.
机械因素在静脉移植物后新生内膜增生中起重要作用,但机制尚不完全清楚。在这里,我们研究了微小 RNA-33(miR-33)在静脉移植物后动脉机械拉伸诱导的新生内膜增生中的作用。
通过“套管”技术生成移植静脉。在 1、2 和 4 周的移植物中,新生内膜增生和细胞增殖明显增加,miR-33 表达减少。相反,骨形态发生蛋白 3(BMP3)的表达增加,BMP3 是 miR-33 的一个假定靶点,而 BMP3 的潜在下游靶点 smad2 和 smad5 的磷酸化也增加。miR-33 模拟物/抑制剂和双荧光素酶报告基因检测证实了 miR-33 和 BMP3 的相互作用。miR-33 模拟物减弱,而 miR-33 抑制剂加速静脉平滑肌细胞(SMC)的增殖。此外,重组 BMP3 增加 SMC 增殖和 P-smad2 和 P-smad5 水平,而 BMP3 靶向 siRNA 则有相反的效果。然后,通过体外 FX4000 循环拉伸加载系统将静脉 SMC 暴露于 10%-1.25Hz 循环拉伸(动脉拉伸)下,以模拟动脉机械条件。动脉拉伸增加了静脉 SMC 的增殖,抑制了 miR-33 的表达,但增强了 BMP3 的表达和 smad2 和 smad5 的磷酸化。此外,体内血管周围多点注射表明,agomiR-33 不仅减弱了 BMP3 的表达和 smad2 和 smad5 的磷酸化,而且还减缓了移植静脉中的新生内膜形成和细胞增殖。agomiR-33 对移植静脉的这些作用可以通过局部注射 BMP3 慢病毒来逆转。
miR-33-BMP3-smad 信号通路可防止静脉 SMC 增殖对动脉拉伸的反应。miR-33 是一种可减轻移植物新生内膜增生的靶点,可能具有潜在的临床应用价值。